Spevigo (spesolimab-sbzo) is a prescription medication used to treat moderate to severe plaque psoriasis in adults. It is administered as an intravenous infusion under the supervision of a healthcare provider.

Uses:

Spevigo is used to treat moderate to severe plaque psoriasis, which is a chronic autoimmune disease that affects the skin. This medication helps reduce scaly and itchy patches on the skin, improve overall skin appearance, and slow down the progression of the disease.

HOW TO USE:

Spevigo is administered as an intravenous infusion, which should be performed by a healthcare provider in a medical setting. Patients should not attempt to self-administer the medication.

Dosage:

The recommended dosage is 400mg every four weeks for three doses, followed by 400mg every eight weeks thereafter.

Mechanism of Action:

Spevigo works by targeting the protein interleukin-23 (IL-23), which plays a critical role in the inflammatory response in psoriasis. By blocking IL-23, Spevigo can help reduce inflammation, improve skin symptoms, and prevent further progression of the disease.

Storage Conditions:

Spevigo should be stored in a refrigerator at a temperature between 2°C to 8°C. The medication should be protected from light, and once removed from the refrigerator, should be used within 24 hours.

Precautions:

• Spevigo can increase the risk of infections, including tuberculosis and bacterial, fungal, and viral infections. Patients should be screened for tuberculosis before starting treatment and should not receive live vaccines while taking Spevigo.
• Patients should inform their healthcare provider if they have a history of inflammatory bowel disease before starting treatment with Spevigo.
• Use with caution in patients with a history of recurrent infections, and those with a history of malignancy.

Interactions:

• Spevigo may interact with certain medications that suppress the immune system, such as corticosteroids and other biologic medications. Patients should inform their healthcare provider of all medications they are taking before starting treatment with Spevigo.

Contraindications:

• Spevigo is contraindicated in patients with a history of severe allergic reactions to spesolimab-sbzo or any of its components.

Side Effects:

The most common side effects of Spevigo include infections, injection site reactions, headache, and diarrhea. Serious adverse events are relatively rare but may include anaphylaxis or other allergic reactions, injection site infections, and pneumonia. Patients should inform their healthcare provider of any unusual or unexpected reactions while taking Spevigo.

Overdose:

There are no reported cases of overdose associated with Spevigo.

In conclusion, Spevigo (spesolimab-sbzo) is a prescription medication used to treat moderate to severe plaque psoriasis in adults. It is administered as an intravenous infusion under the supervision of a healthcare provider. The recommended dosage is 400mg every four weeks for three doses, followed by 400mg every eight weeks thereafter. Spevigo blocks interleukin-23, reducing inflammation and improving skin symptoms. It should be stored in a refrigerator, and patients should be screened for tuberculosis and monitored for infections and potential allergic reactions. Common side effects include infections, injection site reactions, headache, and diarrhea. Serious adverse events are rare, and no cases of overdose have been reported.